Mitochondrial structure alteration in human prostate cancer cells upon initial interaction with a chemopreventive

Chengsen Xue, Hilda A Pasolli, Irene Piscopo

  • 1Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. jen-wei_chiao@nymc.edu.

Abstract

Insights

Phenethyl isothiocyanate (PEITC), found in cruciferous vegetables, targets mitochondria to inhibit prostate cancer cell growth. This chemopreventive agent disrupts mitochondrial structure and induces apoptosis, offering a novel therapeutic strategy.

Area of Science:

  • Cell Biology
  • Cancer Research
  • Biochemistry

Background:

  • Phenethyl isothiocyanate (PEITC) is a natural chemopreventive agent found in cruciferous vegetables.
  • PEITC inhibits prostate cancer progression by targeting DNA hypermethylation and histone deacetylases.
  • The initial cellular organelle interacting with PEITC remains largely undescribed.

Purpose of the Study:

  • To identify the primary cellular organelle targeted by PEITC in human prostate cancer cells.
  • To elucidate the early cellular events following PEITC exposure.

Main Methods:

  • Human prostate cancer LNCaP cells were treated with PEITC.
  • Transmission electron microscopy was used to examine cellular fine structure.
  • Mitochondrial membrane potential, cytochrome c release, and apoptosis were assessed.
  • Mitochondria were isolated to analyze protein expression.

Main Results:

  • PEITC induced significant mitochondrial structural alterations, including condensation and cristae disruption.
  • Autophagy markers (smooth endoplasmic reticulum, vacuoles) increased.
  • Early apoptotic events, such as cytochrome c release and mitochondrial membrane potential disruption, were observed.
  • Reduced expression of mitochondrial outer membrane protein associated with the permeability transition pore was noted.

Conclusions:

  • Mitochondria are likely the primary organelle targeted by PEITC.
  • PEITC acts as a mitochondria-interacting agent, contributing to its chemopreventive effects against cancer.